ClinicalTrials.gg
RecruitingNCT06815081CapOGTTUpdated Apr 13, 2026

Capillary OGTT Study

An observational study in Type 1 Diabetes (T1D) and Type 2 Diabetes, sponsored by University of Oxford. Recruiting at 4 sites in United Kingdom. Open to participants aged Up to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by University of Oxford · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
135
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 41 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.

Planned enrollment
27th of 54
135 · median 133
Started
2024
with 5 others
Observational
54 of 268
14 open now
Primary completion
2027-02
later than 18 of 40 live
Registered
252nd of 268
by date
Lead sponsor
7 of 268
University of Oxford

Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 27th largest by planned enrollment of the 54 observational ones that give a count, is one of 6 that started in 2024, is one of 54 observational ones, reaches primary completion later than 18 of the 40 other live ones, and was the 252nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: Up to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, or all of them as a file.
02

Study summary

Type 1 diabetes (T1D) is a chronic condition, affecting 1 in 490 children under the age of 15 years. It is caused by the immune system damaging the pancreas, the organ which makes insulin. T1D has recognised stages before symptoms develop, providing an opportunity for early diagnosis, education and treatment which may delay the onset of symptoms.

Type 2 diabetes (T2D) is also a chronic condition where the body cannot make enough insulin, or cannot respond to the insulin properly. It is usually related to obesity, rather than an immune problem. It is more common in adults, but the early stages often start in childhood (up to 1 in 4 children in some clinics). Like T1D, early detection can delay onset of T2D, or even prevent it altogether.

Early diagnosis of T1D or T2D often relies on a test called the oral glucose tolerance test (OGTT), which is commonly used but not well tolerated, possibly because it requires a drip inserted into the vein, and several blood samples taken over 2-3 hours in a healthcare setting.

Our study aims to test whether we can do an OGTT using a finger-prick to test glucose, at home. We call this the 'GTT@home'. The finger-prick creates a drop of blood, which is done before and two hours after drinking a sugary drink. We will also explore whether a continuous glucose monitor (CGM), which reads glucose levels through the skin could be an alternative. We plan to recruit 90 children and young people, across two groups to assess the GTT@home.

To understand the experiences of those involved in monitoring, we will invite young people, parents and healthcare workers to take part in an interview, to understand the impact of testing to predict clinical T1D.

Group 1 will assess the accuracy of measuring glucose from a finger-prick blood test when compared to a blood test from the vein. We will recruit individuals who are having an OGTT as part of a research study, for clinical care or if they have agreed to have an OGTT for this study. Those with T1D will be invited to wear a CGM to explore its use as an additional, practical alternative.

Groups 2 and 3 will assess how well the GTT@home test works when done at home and how acceptable it is. This will only be offered to those known to be at risk of T1D.

These studies will help us to understand if the GTT@home can be used in routine care.

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Type 2 Diabetes

Keywords

  • Capillary
  • Glucose
  • Oral glucose tolerance test
  • Method Comparison
  • Feasibility
  • Acceptability
  • Type 1 diabetes
  • Monitoring
  • Follow-up
  • Screening
  • Type 2 diabetes
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Cohort 1 - Children \< 18 years of age. To get a spread of glucose values, we will aim to recruit approximately equal numbers of participants with normoglycaemia, dysglycaemia and hyperglycaemia.

Cohort 1 CGM sub-study - Children \< 18 years of age, who have T1D stage 1, 2 or 3 and undergoing an OGTT in cohort 1.This sub-study will be additional and optional to cohort 1.

Cohort 2 - Children \< 18 years of age, who are identified as having stage 1, 2 or 3 T1D will be invited to take part in an OGTT at home.

Cohort 3 - Children \< 18 years of age, who are identified as having pre-T2D.

Qualitative sub-study - Young people ≥ 15 years old with T1D stage 1, 2 or recent stage 3 (up to 12 months), who have been involved in metabolic follow-up, will be invited to take part. Parents of a child (of any age) with T1D stage 1, 2 or recent stage 3 will also be invited. Healthcare professionals involved in delivering metabolic follow-up for children with diabetes antibodies will also be invited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1

  • Willing and able to give for participation, or assent with parental consent
  • Aged \< 18 years old
  • Able to consume oral glucose drink within 10 minutes
  • Undergoing an OGTT, or consent to have one

Cohort 2

  • Positive for two or more islet autoantibodies at any time
  • Willing and able to give informed consent for participation, or assent with parental consent
  • Aged \< 18 years old
  • Able to consume oral glucose drink within 10 minutes

CGM sub-study

  • Willing and able to give informed consent for participation, or assent with parental consent
  • Aged \< 18 years old
  • Able to consume oral glucose drink within 10 minutes
  • Confirmed to have stage 1, 2 or 3 T1D
  • Participation in Cohort 1

Qualitative sub-study

  • Willing and able to give informed consent for participation, or assent with parental consent Then EITHER
  • A young person positive for two or more islet autoantibodies (15 years old and above) at any time, or parent of a young person who has experienced a metabolic test e.g. OGTT OR
  • A healthcare professional involved in delivering metabolic testing

Cohort 3

  • Prediabetes diagnosis as above
  • Willing and able to give informed consent for participation, or assent with parental consent
  • Aged \< 18 years old
  • Able to consume oral glucose drink within 10 minutes

Exclusion criteria

Exclusion Criteria:

Cohort 1

  • Any known haemoglobinopathy
  • Cystic fibrosis related diabetes
  • Non-English speaker

Cohort 2

  • Any known haemoglobinopathy
  • Known clinical diabetes and on treatment
  • Non-English speaker
  • No recent weight available (within 3 months of study visit) and unable to obtain new weight measurement

CGM sub-study

  • Any known haemoglobinopathy
  • Cystic fibrosis related diabetes
  • Non-English speaker
  • Any active skin issue which would prevent the use of a CGM device

Qualitative sub-study

  • Non-English speaker

Cohort 3

  • Known clinical diabetes and on treatment
  • Non-English speaker
  • No recent weight available (within 3 months of study visit) and unable to obtain new weight measurement
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
135 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1 (Simultaneous venous and capillary OGTT)

    To assess the ability of the capillary OGTT to be a reliable and acceptable alternative to the standard venous OGTT in children, investigators will aim to capture a spread of glucose values across the whole diagnostic range. This will be undertaken in clinical and research settings, led by either a healthcare professional or research nurse. Children undergoing a standard venous OGTT will be invited to complete a capillary OGTT. Both venous and capillary samples will be collected at the same time. Investigators will also invite children with stage 3 (clinical) T1D to capture glucose levels in the hyperglycaemic range. These participants will receive a smaller glucose dose for their OGTT (1g/kg, max dose 75g), to attenuate their glucose rise and allow the comparison of clinically meaningful glucose values. Participants will be asked to complete a questionnaire following the OGTT to obtain information about acceptability.

  • Cohort 2 (Capillary OGTT at home)

    In this cohort (running concurrently alongside cohort 1) investigators aim to assess the acceptability and feasibility of a capillary OGTT device in children and young people with early-stage (known stage 1 or 2) T1D. This will take place in the home of participants, with written and video instructions provided. Children known to be positive for ≥ 2 IAb will be invited to take part and will be sent a capillary OGTT test kit which will include a glucose drink, lancets and instructions (written and video). They will fast overnight (from midnight the night before, for a minimum of 8 hours) before completing a 2-hour OGTT using the test kit and instructions provided. Glucose samples will be collected at 0 and 120 minutes. Participants will be asked to complete a questionnaire following completion of the OGTT, to obtain information about acceptability.

  • Cohort 1 (CGM sub-study)

    In this sub-study investigators aim to explore the ability of CGM to be an alternative to the standard venous OGTT. A subgroup of participants in cohort 1 with known T1D (stage 1, 2 or 3) will be invited to wear a CGM sensor for up to 10 days, which will be worn during their OGTT, at home during a standard mixed meal and free-living. Whilst wearing the CGM at home, participants will be asked to consume a liquid mixed meal (Ensure Plus, 6ml/kg maximum 360ml, preceded by an 8-hour fast) and complete a 3-day food diary, by photographing the largest meal of the day to allow estimation of carbohydrate intake (not the same day as the OGTT or liquid mixed meal). Participants will then be asked to complete a questionnaire to obtain information about acceptability.

  • Qualitative sub-study

    To understand the factors that contribute to uptake of monitoring offered to children at risk of type 1 diabetes, investigators will invite a small number of young people (aged 15-18) and parents to take part in a semi-structured interview. Investigators will also invite healthcare professionals involved in delivering metabolic testing as part of follow-up to take part in semi-structured interviews, to understand their views on the factors which may influence future implementation into clinical care.

  • Cohort 3 (Pre-clinical type 2 diabetes)

    In this cohort (running concurrently alongside cohort 1) we aim to assess the acceptability and feasibility of a capillary OGTT device in children with pre-clinical T2D at home. This will take place in the home of participants, with written or video instructions provided. For cohort 3, children with raised BMI (≥91st centile) and any marker of insulin resistance: HbA1c 39-47mmol, or known impaired fasting glucose (5.6 - 6.9 mmol/L), or impaired glucose tolerance (7.8 - 11.0 mmol/L), will be invited to take part. They will fast overnight (from midnight the night before, for a minimum of 8 hours) before completing a 2-hour OGTT using the test kit and instructions provided. Participants will be asked to complete a questionnaire following completion of the OGTT, to obtain information about acceptability.

06

What researchers measure

Primary outcomes

  1. To determine the agreement of capillary blood glucose levels to venous blood glucose levels during a standard OGTT

    Agreement between capillary and blood glucose measures.

    Time frame: From enrolment to end of study visit on day 1.

  2. To assess the feasibility of using the capillary OGTT device in the home environment

    1. Proportion of successful glucose readings at 0, 120 minutes 2. Proportion of errors/missing glucose readings 3. Proportion of adverse events

    Time frame: From enrolment to end of study visit on day 1

Secondary outcomes

  1. To determine the diagnostic accuracy of capillary blood glucose levels at diagnostic thresholds

    Sensitivity and specificity of capillary glucose at 5.6mmol/L, 7.0mmol/L (fasting), 11.1 mmol/L (60 min), and 7.8mmol/L and 11.1mmol/L (120 min).

    Time frame: From enrolment to end of study visit on day 1.

  2. Assess the acceptability of the capillary OGTT device

    Acceptability by questionnaire (Parent +/- child), using either a standard 7-point Likert scale (1 - not painful at all, 7 - very painful) for participants aged 16 and above, or Wong Baker Faces pain scale (0 - no hurt, 10 - hurts worst) for participants aged under 16.

    Time frame: From enrolment to end of study visit on day 1.

  3. To assess the in-depth experience of participants attending study visits involving a metabolic test or assessment

    Analysis of qualitative interviews from young people.

    Time frame: From enrolment to end of study visit on day 1

  4. To assess the in-depth experience of parents attending study visits with their child involving a metabolic test or assessment

    Analysis of qualitative interviews from parents.

    Time frame: From enrolment to end of study visit on day 1.

  5. To assess the in-depth views of healthcare professionals involved in the delivery of a metabolic test or assessment of a child

    Analysis of qualitative interviews from healthcare professionals.

    Time frame: From enrolment to end of study visit on day 1.

Other outcomes

  1. To explore the diagnostic accuracy of CGM to define T1D stages during a standard OGTT

    Sensitivity/specificity of sensor glucose levels at diagnostic thresholds.

    Time frame: From enrolment to end of study visit at day 10.

  2. To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living

    Sensor glucose variability (coefficient of variation (%CV)), during home meals, across different T1D stages.

    Time frame: From enrolment to end of study visit on day 10.

  3. To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living

    Sensor glucose variability (mean amplitude of glycaemic excursion (MAGE) mmol/L)), during home meals, across different T1D stages.

    Time frame: From enrolment to end of study visit on day 10.

  4. To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living

    Sensor glucose variability (low blood glucose index (LBGI)), during home meals, across different T1D stages.

    Time frame: From enrolment to end of study visit on day 10.

  5. To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living

    Sensor glucose variability (high blood glucose index (HBGI)), during home meals, across different T1D stages.

    Time frame: From enrolment to end of study visit on day 10.

  6. To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living

    Sensor glucose variability (average daily risk range (ADRR)), during home meals, across different T1D stages.

    Time frame: From enrolment to end of study visit on day 10.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Wilson DM, Pietropaolo SL, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck AK, Vasudevan MM, McKay SV, Sherr JL, Herold KC, Dunne JL, Greenbaum CJ, Lord SM, Haller MJ, Schatz DA, Atkinson MA, Nelson PW, Pietropaolo M; Type 1 Diabetes TrialNet Study Group. CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care. 2023 Mar 1;46(3):526-534. doi: 10.2337/dc22-1297. PubMed 36730530 ↗
  • Ylescupidez A, Speake C, Pietropaolo SL, Wilson DM, Steck AK, Sherr JL, Gaglia JL, Bender C, Lord S, Greenbaum CJ. OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody-Positive Individuals. J Clin Endocrinol Metab. 2023 Dec 21;109(1):57-67. doi: 10.1210/clinem/dgad472. PubMed 37572381 ↗
  • Liu Y, Rafkin LE, Matheson D, Henderson C, Boulware D, Besser REJ, Ferrara C, Yu L, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study. Diabet Med. 2017 Jul;34(7):934-937. doi: 10.1111/dme.13338. Epub 2017 Mar 8. PubMed 28226181 ↗
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008 Apr;61(4):344-9. doi: 10.1016/j.jclinepi.2007.11.008. PubMed 18313558 ↗
  • Dunseath GJ, Bright D, Luzio SD. Comparative Accuracy Evaluation of a Blood Glucose Meter With Novel Hematocrit Correction Technology, With Three Currently Used Commercially Available Blood Glucose Monitoring Systems. J Diabetes Sci Technol. 2019 May;13(3):568-574. doi: 10.1177/1932296818821389. Epub 2019 Jan 9. PubMed 30623673 ↗
  • Ginsberg BH. Factors affecting blood glucose monitoring: sources of errors in measurement. J Diabetes Sci Technol. 2009 Jul 1;3(4):903-13. doi: 10.1177/193229680900300438. PubMed 20144340 ↗
  • Bethel MA, Price HC, Sourij H, White S, Coleman RL, Ring A, Kennedy IE, Tucker L, Holman RR. Evaluation of a self-administered oral glucose tolerance test. Diabetes Care. 2013 Jun;36(6):1483-8. doi: 10.2337/dc12-0643. Epub 2013 Jan 15. PubMed 23321216 ↗
  • Dunseath GJ, Bright D, Jones C, Dowrick S, Cheung WY, Luzio SD. Performance evaluation of a self-administered home oral glucose tolerance test kit in a controlled clinical research setting. Diabet Med. 2019 Jul;36(7):862-867. doi: 10.1111/dme.13961. Epub 2019 Apr 26. PubMed 30972793 ↗
  • Bruns DE, Metzger BE, Sacks DB. Diagnosis of Gestational Diabetes Mellitus Will Be Flawed until We Can Measure Glucose. Clin Chem. 2020 Feb 1;66(2):265-267. doi: 10.1093/clinchem/hvz027. No abstract available. PubMed 32040567 ↗
  • Plebani M. The detection and prevention of errors in laboratory medicine. Ann Clin Biochem. 2010 Mar;47(Pt 2):101-10. doi: 10.1258/acb.2009.009222. Epub 2009 Dec 1. PubMed 19952034 ↗
  • Bogdanet D, O'Shea P, Lyons C, Shafat A, Dunne F. The Oral Glucose Tolerance Test-Is It Time for a Change?-A Literature Review with an Emphasis on Pregnancy. J Clin Med. 2020 Oct 27;9(11):3451. doi: 10.3390/jcm9113451. PubMed 33121014 ↗
  • Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17. PubMed 25519451 ↗
  • Simmons KM, Sosenko JM, Warnock M, Geyer S, Ismail HM, Elding Larsson H, Steck AK. One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes. J Clin Endocrinol Metab. 2020 Nov 1;105(11):e4094-101. doi: 10.1210/clinem/dgaa592. PubMed 32844178 ↗
  • Sosenko JM, Skyler JS, Palmer JP; Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). Curr Diab Rep. 2015 Aug;15(8):49. doi: 10.1007/s11892-015-0626-1. PubMed 26077017 ↗
  • Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18. PubMed 24550217 ↗
  • Bediaga NG, Li-Wai-Suen CSN, Haller MJ, Gitelman SE, Evans-Molina C, Gottlieb PA, Hippich M, Ziegler AG, Lernmark A, DiMeglio LA, Wherrett DK, Colman PG, Harrison LC, Wentworth JM. Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia. 2021 Nov;64(11):2432-2444. doi: 10.1007/s00125-021-05523-2. Epub 2021 Aug 2. PubMed 34338806 ↗
  • Weiss A, Zapardiel-Gonzalo J, Voss F, Jolink M, Stock J, Haupt F, Kick K, Welzhofer T, Heublein A, Winkler C, Achenbach P, Ziegler AG, Bonifacio E; Fr1da-study group. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia. 2022 Dec;65(12):2121-2131. doi: 10.1007/s00125-022-05780-9. Epub 2022 Aug 27. PubMed 36028774 ↗
  • Driscoll KA, Tamura R, Johnson SB, Gesualdo P, Clasen J, Smith L, Jacobsen L, Elding Larsson H, Haller MJ; TEDDY Study Group. Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study. Pediatr Diabetes. 2021 Mar;22(2):360-368. doi: 10.1111/pedi.13149. Epub 2021 Jan 6. PubMed 33179853 ↗
  • Sims EK, Geyer S, Johnson SB, Libman I, Jacobsen LM, Boulware D, Rafkin LE, Matheson D, Atkinson MA, Rodriguez H, Spall M, Elding Larsson H, Wherrett DK, Greenbaum CJ, Krischer J, DiMeglio LA; Type 1 Diabetes TrialNet Study Group. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care. 2019 Dec;42(12):2228-2236. doi: 10.2337/dc19-0593. Epub 2019 Sep 26. PubMed 31558546 ↗
  • Quinn LM, Swaby R, Tatovic D, Narendran P, Besser REJ, Dayan CM. What does the licensing of teplizumab mean for diabetes care? Diabetes Obes Metab. 2023 Aug;25(8):2051-2057. doi: 10.1111/dom.15071. Epub 2023 Apr 24. No abstract available. PubMed 36999237 ↗
  • Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. PubMed 31180194 ↗
  • Hummel S, Carl J, Friedl N, Winkler C, Kick K, Stock J, Reinmuller F, Ramminger C, Schmidt J, Lwowsky D, Braig S, Dunstheimer D, Ermer U, Gerstl EM, Weber L, Nellen-Hellmuth N, Bramswig S, Sindichakis M, Tretter S, Lorrmann A, Bonifacio E, Ziegler AG, Achenbach P; Fr1da Study Group. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023 Sep;66(9):1633-1642. doi: 10.1007/s00125-023-05953-0. Epub 2023 Jun 17. PubMed 37329450 ↗
  • Barker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, Norris JM, Klingensmith GJ, Rewers M; DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004 Jun;27(6):1399-404. doi: 10.2337/diacare.27.6.1399. PubMed 15161795 ↗
  • Krischer JP, Liu X, Vehik K, Akolkar B, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG, Lernmark A; TEDDY Study Group. Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. Diabetes Care. 2019 Jun;42(6):1051-1060. doi: 10.2337/dc18-2282. Epub 2019 Apr 9. PubMed 30967432 ↗
  • McQueen RB, Geno Rasmussen C, Waugh K, Frohnert BI, Steck AK, Yu L, Baxter J, Rewers M. Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. Diabetes Care. 2020 Jul;43(7):1496-1503. doi: 10.2337/dc19-2003. Epub 2020 Apr 23. PubMed 32327420 ↗
  • American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S20-S42. doi: 10.2337/dc24-S002. PubMed 38078589 ↗
  • Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark A, Hagopian WA, Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E; TEDDY Study Group. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015 May;58(5):980-7. doi: 10.1007/s00125-015-3514-y. Epub 2015 Feb 10. PubMed 25660258 ↗
  • Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013 Jun 19;309(23):2473-9. doi: 10.1001/jama.2013.6285. PubMed 23780460 ↗
  • Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. PubMed 26404926 ↗
  • TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann N Y Acad Sci. 2008 Dec;1150:1-13. doi: 10.1196/annals.1447.062. PubMed 19120261 ↗
  • Besser REJ, Bell KJ, Couper JJ, Ziegler AG, Wherrett DK, Knip M, Speake C, Casteels K, Driscoll KA, Jacobsen L, Craig ME, Haller MJ. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2022 Dec;23(8):1175-1187. doi: 10.1111/pedi.13410. Epub 2022 Sep 30. No abstract available. PubMed 36177823 ↗
  • Besser REJ, Ng SM, Gregory JW, Dayan CM, Randell T, Barrett T. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Child. 2022 Sep;107(9):790-795. doi: 10.1136/archdischild-2021-321864. Epub 2021 Nov 5. PubMed 34740879 ↗

Individual participant data

Plan to share: Yes — Dates of birth will not be shared, but ages (possibly grouped) will be provided.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD and supporting information will be availabile once the primary paper for the study has been published.

Access criteria: Subject to participant consent, data will be shared with other researchers for research projects that have appropriate ethical approval. Requests for access to the data will be controlled by the Data Access Committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 7, 2025
StartActual
Feb 29, 2024
Primary completionEst.
Feb 28, 2027
CompletionEst.
Aug 31, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06815081
Collaborators
University of Bristol, Yale University, Oxford University Hospitals NHS Trust, Nottingham University Hospitals NHS Trust, Cardiff and Vale University Health Board, Royal London Hospital, Barts Health NHS Trust
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Feb 29, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Rabbi Swaby, BMBS
Contact
rabbi.swaby@well.ox.ac.uk
+44 1865287578
Claire Scudder
Contact
capogtt@ndm.ox.ac.uk
+44 (0)7765 932065

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion